|
Código del ensayo SB27-1005. Samsung Bioepis Co., Ltd. |
|
Ensayo A Phase I, Randomised, Double-blind, Three-arm, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in subjects with Stage II-IIIA Non-small Cell Lung Cancer Following Complete Resection and Adjuvant Platinum-based Chemotherapy |
|
Estado Abierto a inclusión |
|
Localización Tumoral Tórax |
|
Tipo de tumor Pulmón |
|
Tipo de ensayo Ensayo de Fase I |
|
Tipo de tratamiento Inmunoterapia |
|
Situación clínica Adyuvancia |
|
Centro |
